Is PT-141 (Bremelanotide) Legal in California? How to Access It Legally

HealthRX.com

Vyleesi is the FDA-approved, prescription-only form

Print or save as PDF

Key numbers

  • 1.75 mgVyleesi dose per prefilled autoinjector injection; prescription-only FDA-approved productSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 45 minutesMinimum wait before sexual activity when injecting Vyleesi as needed; max one dose in 24 hoursSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Phase 3 trial share with nausea on Vyleesi, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • FDA status / Approved as Vyleesi (NDA 210557) on June 21, 2019; 1.75 mg subcutaneous autoinjector; prescription only [1][2]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
  • Compounded or research PT-141 / Not Vyleesi and not an FDA-approved drug [1][3]
  • FDA bulk-substance lists / Bremelanotide is not listed on FDA's bulk-substance lists or the HHS October 2026 draft peptide enforcement-discretion list [4][5][6]
  • Boxed warning / None [1]
  • Main label contraindication / Uncontrolled hypertension or known cardiovascular disease [1]
  • Access route / A prescription for Vyleesi [1][2]

What is the federal legal status?

Bremelanotide is FDA-approved as Vyleesi under NDA 210557; the original approval date was June 21, 2019 [2]. It is a 1.75 mg subcutaneous injection in a prefilled autoinjector and is prescription only [1][2]. The FDA-approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for postmenopausal women or men, and not to enhance sexual performance [1]. Vyleesi has no boxed warning [1].

What about compounded or research PT-141?

Vyleesi is the FDA-approved bremelanotide product. Products sold as PT-141, compounded bremelanotide or research-use peptide are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][3]. Bremelanotide does not appear on FDA's page of bulk substances that may raise significant safety risks, or in any category on FDA's bulk-substance lists, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][5][6].

Does California law change this?

Federal approval and prescription-only status apply in every state [1][2]. California's own rules on prescribing, telehealth and compounding are not described here, so no California-specific legal claim is made about any particular telehealth prescription or compounded product.

What people on Reddit report

These are Reddit posts about getting compounded tirzepatide shipped to California. They describe how state rules and telehealth shipping have affected access to that compounded drug.

BBCrocker · tirzepatidecompound

California has particularly strict rules around compounding so you have fewer options as a consequence.

Commenter says California's compounding rules limit how many pharmacies can ship there, for compounded tirzepatide.

Read the source discussion

Splendidmuffin · tirzepatidecompound

Tbh I prefer California's stricter regulations. I'm injecting something into my body and essentially doing a hail Mary it's not poison because I don't have a lab to test what it is

Commenter on compounded tirzepatide says they welcome California's stricter rules because they cannot verify what they inject.

Read the source discussion

How is Vyleesi used?

Vyleesi is prescription only [1][2]. The label says to inject 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours; more than 8 doses per month is not recommended; and to stop after 8 weeks if there is no improvement [1]. The duration of effect after a dose is unknown [1].

What does the label say to watch for?

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1]. The label says it is not recommended for patients at high risk for cardiovascular disease and says to assess cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1]. In the phase 3 trials, nausea occurred in 40.0% on Vyleesi vs 1.3% on placebo; flushing 20.3% vs 0.3%; injection site reactions 13.2% vs 8.4%; headache 11.3% vs 1.9%; and vomiting 4.8% vs 0.2% [1]. Focal hyperpigmentation was reported by 1% of patients who received up to 8 doses per month vs none on placebo, with higher risk in darker skin and with daily dosing [1].

What is the practical answer?

Access to bremelanotide means a prescription for Vyleesi, the only FDA-approved bremelanotide product, for its labeled HSDD population [1][2]. Compounded and research PT-141 are not FDA-approved drugs [1][3].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, which group is the FDA-approved use of Vyleesi for?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is PT-141 legal in California?
Bremelanotide is FDA-approved and prescription-only as Vyleesi, for premenopausal women with acquired, generalized HSDD [1][2]. Compounded and research PT-141 are not FDA-approved drugs [1][3].
Can I get PT-141 by telehealth in California?
Vyleesi is a prescription-only drug [1][2]. Telehealth is one way a prescription could be written, but the label and FDA approval letter do not address telehealth.
Is compounded PT-141 legal?
Compounded PT-141 is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][3]. Bremelanotide is not on FDA's bulk-substance lists or the HHS October 2026 draft peptide list [4][5][6].
What is Vyleesi approved for?
Vyleesi is approved for premenopausal women with acquired, generalized HSDD. It is not indicated for men, postmenopausal women, or enhancing sexual performance [1].
What are the main label warnings?
The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease and says it is not recommended for patients at high risk for cardiovascular disease [1]. In phase 3 trials, nausea occurred in 40.0% vs 1.3% on placebo, flushing in 20.3% vs 0.3%, and headache in 11.3% vs 1.9% [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Where can I buy PT-141 peptide for men?

Vyleesi is the only FDA-approved bremelanotide product, and it is prescription only. Its label does not indicate it for men. Products sold as PT-141, compounded bremelanotide or research-use peptides are not Vyleesi and are not FDA-approved drugs.

What does PT-141 make you feel like?

The reported effects are nausea, flushing, injection site reactions, headache and vomiting. Nausea occurred in 40.0% on Vyleesi vs 1.3% on placebo, and flushing in 20.3% vs 0.3%. The reported side effects are the only description of how it affects people.

Show all 7 referencesHide references
PT-141 California: evidence summary chart
Image: HealthRX.com. Full PT-141 California guide and sources at healthrx.com/peptide-legal-pt-141.